FDA Launches Natural History Grant Program
The program is intended to provide support to ongoing efforts in rare disease product development.
FDA launched the Natural History Grant Program, a new grants program to fund natural history studies of rare diseases. The agency made the announcement in a blog post on Feb. 29, 2016, officially known as Rare Disease Day 2016.
Katherine Needleman, PhD, the director of orphan products grants program of FDA’s Office of Orphan Products Development, published the blog on FDA’s website, saying, “a lack of understanding of the natural history is often a major obstacle to developing life-saving products for patients with rare disease.”
The grants program will provide two funding levels for those interested in conducting natural history studies:
- A maximum of $400,000 in total costs per year, up to five years for clinical examination of affected individuals
- A maximum of $150,000 in total costs per year up to two years for retrospective natural history studies or survey studies.
According to FDA, patient advocacy groups play a “critical role” in collecting natural history data, but they are often prevented from conducting studies because of a lack of funding. Needleman says in the blog post that FDA hopes the program will assist in accelerating the development of rare disease treatments.
A grants program like the National History Grant Program could provide a viable solution for drug developers conducting clinical trials of rare diseases and could help manufacturers provide supplemental data for trials with small numbers of participants. In January 2015 FDA released a 73-page document expressing concerns about clinical trial data from the drug eteplirsen, STAT reported. Eteplirsen is intended to treat children suffering from Duchenne muscular dystrophy, and was developed by Sarepta Therapeutics. Sarepta’s clinical data on the drug came from a small trial with a sample size of 12 boys. FDA expressed concern that such a small sample may not demonstrate the drugs effectiveness.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
